Scholarlink

<p>Acute kidney injury (AKI) is a serious condition marked by a rapid decline in renal function, often leading to long-term complications. Mesenchymal stromal cells (MSCs) and their derivatives, including conditioned medium (CM) and extracellular vesicles (EVs), show promise as regenerative therapies. However, the comparative efficacy of CM and EVs and the development of clinically translatable interventions remains underexplored. This study systematically compared the renoprotective effects of CM and EVs derived from human umbilical cord MSCs in a murine cisplatin-induced AKI model, using a therapeutically feasible dose. Both treatments improved renal function, reduced histological damage, preserved mitochondrial integrity, energy metabolism, and antioxidant response. Notably, EVs induced the greatest proliferative response in renal tubular cells. To further enhance the regenerative potential of EVs, we engineered MSCs to overexpress nicotinamide phosphoribosyltransferase (NAMPT), a metabolic enzyme that plays a key role in NAD<sup>+</sup> biosynthesis. NAMPT-transfected MSCs released NAMPT-enriched EVs, which more effectively enhanced cell viability, reduced apoptosis, and protected mitochondria in cisplatin-damaged tubular cells in vitro compared to EV-GFP. In mice with AKI, NAMPT-enriched EVs improved renal function and repaired damage by enhancing renal NAMPT and NAD<sup>+</sup> levels, promoting tubular cell regeneration. Mechanistically, the amelioration of mitochondrial function was related to increased PGC1α and SIRT3 and consequently SOD2 and ATP5i expression. These findings highlight the therapeutic potential of EVs, particularly NAMPT-enriched EVs, in renal repair, supporting their promise as a clinically translatable approach for promoting recovery from AKI and other kidney diseases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NAMPT overexpression enhances the regenerative potential of mesenchymal stromal cell-derived extracellular vesicles in experimental AKI

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月12日

查看全文
  • Simona Buelli,
  • Michelle Prioli Miranda Soares,
  • Anna Pezzotta,
  • Daniela Corna,
  • Piera Trionfini,
  • Luca Perico,
  • Melissa Kosovari,
  • Cinzia Rota,
  • Giuseppe Remuzzi,
  • Ariela Benigni,
  • Marina Morigi,
  • Barbara Imberti

摘要

Acute kidney injury (AKI) is a serious condition marked by a rapid decline in renal function, often leading to long-term complications. Mesenchymal stromal cells (MSCs) and their derivatives, including conditioned medium (CM) and extracellular vesicles (EVs), show promise as regenerative therapies. However, the comparative efficacy of CM and EVs and the development of clinically translatable interventions remains underexplored. This study systematically compared the renoprotective effects of CM and EVs derived from human umbilical cord MSCs in a murine cisplatin-induced AKI model, using a therapeutically feasible dose. Both treatments improved renal function, reduced histological damage, preserved mitochondrial integrity, energy metabolism, and antioxidant response. Notably, EVs induced the greatest proliferative response in renal tubular cells. To further enhance the regenerative potential of EVs, we engineered MSCs to overexpress nicotinamide phosphoribosyltransferase (NAMPT), a metabolic enzyme that plays a key role in NAD+ biosynthesis. NAMPT-transfected MSCs released NAMPT-enriched EVs, which more effectively enhanced cell viability, reduced apoptosis, and protected mitochondria in cisplatin-damaged tubular cells in vitro compared to EV-GFP. In mice with AKI, NAMPT-enriched EVs improved renal function and repaired damage by enhancing renal NAMPT and NAD+ levels, promoting tubular cell regeneration. Mechanistically, the amelioration of mitochondrial function was related to increased PGC1α and SIRT3 and consequently SOD2 and ATP5i expression. These findings highlight the therapeutic potential of EVs, particularly NAMPT-enriched EVs, in renal repair, supporting their promise as a clinically translatable approach for promoting recovery from AKI and other kidney diseases.